Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diabetes herbals recalled

This article was originally published in The Tan Sheet

Executive Summary

Two California firms announce March 23 they have initiated recalls of herbal supplements containing a prescription drug used to treat diabetes. SciQuest Lab's Dimelstat and Diabetic Capital's Dianolyn Capsules contain glyburide, a blood sugar-lowering medication that could cause "life-threatening complications" for diabetes patients, the companies acknowledge. Dianolyn is manufactured in China and then packaged and distributed in the U.S., Diabetic Capital explains. In February, the California Department of Health Services' Food & Drug Branch and FDA prompted a recall of two other supplements that contained glyburide and phenformin (1"The Tan Sheet" Feb. 21, p. 9)
Advertisement

Related Content

Five Chinese Herbals Contain Drug Ingredients, Calif. Health Dept. Warns
Five Chinese Herbals Contain Drug Ingredients, Calif. Health Dept. Warns

Topics

Advertisement
UsernamePublicRestriction

Register

PS091032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel